Although anthracycline (ANT)-based treatment strongly contributes to cancer survivorship, the use of these agents is limited by the risk of cardiotoxicity. For those patients who evolve to heart failure, myocardial regenerative approaches are of particular interest, and a growing body of preclinical studies has been investigating the use of cell therapy for ANT-induced cardiomyopathy (AIC). However, since animal models and modalities of cell therapy are highly heterogeneous between studies, the efficacy of cell therapy for AIC is not clear. Thus, we conducted a systematic review and meta-analysis of experimental studies reporting the use of cell therapy with mesenchymal stromal cells (MSC) or bone marrow mononuclear cells (BMMNC) in animal models of AIC with regard to global cardiac function. The Medline, EMBASE, and Web of Science databases were searched from inception to November 2019. Two reviewers independently extracted data on study quality and the results of left ventricular ejection fraction (LVEF) and fractional shortening (FS) obtained by echocardiography. The quality of outcomes was assessed using the Cochrane, Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES), and SYRCLE bias risk tools. Pooled random-effects modeling was used to calculate pooled mean differences (MD) and 95% confidence intervals (CIs). Twenty-two studies comprising 381 small animals (rabbits and rodents) were included. A pooled meta-analysis of all treatments showed that cell therapy increased LVEF by 9.87% (95% CI 7.25–12.50, P < 0.00001) and FS by 7.80% (95% CI 5.68–9.92, P < 0.00001) in small animals with AIC. Cell therapy with MSC/BMMNC is effective to mitigate the deleterious effects of ANT on cardiac function in preclinical models. Nevertheless, due to the small number of studies and considerable heterogeneity, future translational studies must be designed to diminish between-study discrepancies and increase similarity to the clinical landscape.
Get full access to this article
View all access options for this article.
References
1.
CappettaD, RossiF, PiegariE, QuainiF, BerrinoL, UrbanekK and De AngelisA. (2018). Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res, 127:4–14.
2.
World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019.
3.
PugazhendhiA, EdisonT, VelmuruganBK, JacobJA and KaruppusamyI. (2018). Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci, 200:26–30.
4.
Renu KGA V, BT P and ArunachalamS. (2018). Molecular mechanism of doxorubicin-induced cardiomyopathy—An update. Eur J Pharmacol, 818:241–253.
5.
CardinaleD, ColomboA, BacchianiG, TedeschiI, MeroniCA, VegliaF, CivelliM, LamantiaG, ColomboN, et al. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. 131:1981–1988.
6.
SongboM, LangH, XinyongC, BinX, PingZ and LiangS. (2019). Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett, 307:41–48.
7.
Henriksen PA. (2018). Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart, 104:971–977.
8.
CuomoA, RodolicoA, GaldieriA, RussoM, CampiG, FrancoR, BrunoD, AranL, CarannanteA, et al. (2019). Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients. Card Fail Rev, 5:112–118.
9.
PommierY, LeoE, ZhangH and MarchandC. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol, 17:412–433.
10.
YangF, TevesSS, KempCJ and HenikoffS. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta, 1845:84–89.
11.
ZhangS, LiuX, Bawa-KhalfeT, LuLS, LyuYL, LiuLF and YehET. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med, 18:1639–1642.
12.
GoriniS, De AngelisA, BerrinoL, MalaraN, RosanoG and FerraroE. (2018). Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev, 2018:7582730.
13.
LyuYL, KerriganJE, LinCP, AzarovaAM, TsaiYC, BanY and LiuLF. (2007). Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res, 67:8839–8846.
14.
VejpongsaP and YehET. (2014). Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther, 95:45–52.
15.
ArmenianSH, LacchettiC, BaracA, CarverJ, ConstineLS, DenduluriN, DentS, DouglasPS, DurandJB, et al. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 35:893–911.
16.
SiegelRL, MillerKD and JemalA. (2019). Cancer statistics, 2019. CA Cancer J Clin, 69:7–34.
17.
KoeneRJ, PrizmentAE, BlaesA and KonetySH. (2016). Shared risk factors in cardiovascular disease and cancer. Circulation, 133:1104–1114.
18.
StrongmanH, GaddS, MatthewsA, MansfieldKE, StanwayS, LyonAR, Dos-Santos-SilvaI, SmeethL and BhaskaranK. (2019). Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet, 394:1041–1054.
19.
CuriglianoG, LenihanD, FradleyM, GanatraS, BaracA, BlaesA, HerrmannJ, PorterC, LyonAR, et al. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol, 31:171–190.
20.
MacedoAVS, LyonAR, NascimentoBR, PutzuA, RossiL, CostaRB, et al. (2019). Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. J Am Coll Cardiol CardioOncol, 1:68–79.
21.
VaduganathanM, HirjiSA, QamarA, BajajN, GuptaA, ZahaVG, ChandraA, HaykowskyM, KyB, et al. (2019). Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol, 1:54–65.
22.
ReichardtP, TaboneM-D, MoraJ, MorlandB and JonesRL. (2018). Risk–benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol, 14:2663–2676.
23.
BlanterJB and FrishmanWH. (2019). The preventive role of angiotensin converting enzyme inhibitors/angiotensin-II receptor blockers and beta-adrenergic blockers in anthracycline- and trastuzumab-induced cardiotoxicity. Cardiol Rev, 27:256–259.
da Silva MeirellesL, FontesAM, CovasDT and CaplanAI. (2009). Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 20:419–427.
26.
DolatiS, YousefiM, MahdipourM, Afrasiabi RadA, PishgahiA, NouriM and JodatiAR. (2019). Mesenchymal stem cell and bone marrow mononuclear cell therapy for cardiomyopathy: from bench to bedside. J Cell Biochem, 120:45–55.
27.
TeerlinkJR, MetraM, FilippatosGS, DavisonBA, BartunekJ, TerzicA, GershBJ, PovsicTJ, HenryTD, et al. (2017). Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. Eur J Heart Fail, 19:1520–1529.
28.
FanM, HuangY, ChenZ, XiaY, ChenA, LuD, WuY, ZhangN and QianJ. (2019). Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis. Stem Cell Res Ther, 10:150.
29.
XuR, DingS, ZhaoY, PuJ and HeB. (2014). Autologous transplantation of bone marrow/blood-derived cells for chronic ischemic heart disease: a systematic review and meta-analysis. Can J Cardiol, 30:1370–1377.
30.
FloreaV, RiegerAC, DiFedeDL, El-KhorazatyJ, NatsumedaM, BanerjeeMN, TompkinsBA, KhanA, SchulmanIH, et al. (2017). Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study). Circ Res, 121:1279–1290.
31.
MicheuMM and DorobantuM. (2017). Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World J Stem Cells, 9:68–76.
32.
YunCW and LeeSH. (2019). Enhancement of functionality and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for cardiovascular disease. Int J Mol Sci, 20:982.
33.
BolliR, HareJM, HenryTD, LennemanCG, MarchKL, MillerK, PepineCJ, PerinEC, TraverseJH, et al. (2018). Rationale and design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. Am Heart J, 201:54–62.
34.
de VriesRBM, HooijmansCR, LangendamMW, van LuijkJ, LeenaarsM, Ritskes-HoitingaM and WeverKE. (2015). A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evid Based Preclin Med, 2:1–9 e00007.
35.
PengW, SunJ, ShengC, WangZ, WangY, ZhangC and FanR. (2015). Systematic review and meta-analysis of efficacy of mesenchymal stem cells on locomotor recovery in animal models of traumatic brain injury. Stem Cell Res Ther, 6:47.
36.
ShayaFT, SingK, MilamR, HusainF, Del AguilaMA and PatelMY. (2020). Lipid-lowering efficacy of ezetimibe in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analyses. Am J Cardiovasc Drugs, 20:239–248.
37.
HigginsJPT, ThomasJ, ChandlerJ, CumpstonM, LiT, PageMJ, WelchVA, eds. (2019). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edn. John Wiley & Sons, Chichester (UK).
38.
HooijmansCR, RoversMM, de VriesRB, LeenaarsM, Ritskes-HoitingaM and LangendamMW. (2014). SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol, 14:43.
39.
HigginsJP, ThompsonSG, DeeksJJ and AltmanDG. (2003). Measuring inconsistency in meta-analyses. BMJ, 327:557–560.
40.
IshidaM, TomitaS, NakataniT, FukuharaS, HamamotoM, NagayaN, OhtsuY, SugaM, YutaniC, et al. (2004). Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy. J Heart Lung Transplant, 23:436–445.
41.
ChenM, FanZC, LiuXJ, DengJL, YangQ and HuangDJ. (2006). Cell transplantation with a catheter-based approach: an efficient method for the treatment of heart failure with multiple lesions. Cell Prolif, 39:471–477.
42.
YuQ, LiQ, NaR, LiX, LiuB, MengL, LiutongH, FangW, ZhuN and ZhengX. (2014). Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. Mol Cell Biochem, 387:279–285.
43.
ZengYL, ZhengH, ChenQR, YuanXH, RenJH, LuoXF, ChenP, LinZY, ChenSZ, et al. (2017). Bone marrow-derived mesenchymal stem cells overexpressing MiR-21 efficiently repair myocardial damage in rats. Oncotarget, 8:29161–29173.
44.
ZhangJ, ZhangL, WuQ, LiuH and HuangL. (2013). Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in rats. Mol Med Rep, 7:628–632.
45.
CarvalhoKA, SimeoniRB, Guarita-SouzaLC, FranciscoJC, AbdelwahidE, MyiagueNI, ChachquesJC, RivettiLA, OliveiraL, et al. (2008). Angiogenesis without functional outcome after mononuclear stem cell transplant in a doxorubicin-induced dilated myocardiopathy murine model. Int J Artif Organs, 31(:431–438.
46.
LiTS, TakahashiM, OhshimaM, QinSL, KuboM, MuramatsuK and HamanoK. (2008). Myocardial repair achieved by the intramyocardial implantation of adult cardiomyocytes in combination with bone marrow cells. Cell Transplant, 17:695–703.
47.
NakajimaH, SakakibaraY, TambaraK, MaruiA, YoshimotoM, PremaratneGU, LinX, KanemitsuN, SakaguchiG, et al. (2008). Delivery route in bone marrow cell transplantation should be optimized according to the etiology of heart disease. Circ J, 72:1528–1535.
48.
ArsalanM, DheinS, AupperleH, RastanAJ, BartenMJ, WaltherT, MohrFW and GarbadeJ. (2013). The reverse remodeling effect of mesenchymal stem cells is independent from the site of epimyocardial cell transplantation. Innovations (Phila), 8:433–439.
49.
DengB, WangJX, HuXX, DuanP, WangL, LiY and ZhuQL. (2017). Nkx2.5 enhances the efficacy of mesenchymal stem cells transplantation in treatment heart failure in rats. Life Sci, 182:65–72.
50.
GuoJ, ZhangH, XiaoJ, WuJ, YeY, LiZ, ZouY and LiX. (2013). Monocyte chemotactic protein-1 promotes the myocardial homing of mesenchymal stem cells in dilated cardiomyopathy. Int J Mol Sci, 14:8164–8178.
51.
MaoC, HouX, WangB, ChiJ, JiangY, ZhangC and LiZ. (2017). Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats. Stem Cell Res Ther, 8:18.
52.
OliveiraMS, MeloMB, CarvalhoJL, MeloIM, LavorMS, GomesDA, de GoesAM and MeloMM. (2013). Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J Cancer Sci Ther, 5:52–57.
53.
DiGH, JiangS, LiFQ, SunJZ, WuCT, HuX and DuanHF. (2012). Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model. Cytotherapy, 14:412–422.
54.
MorschbacherPD, Alves GarcezTN, PazAH, MagrissoAB, MelloHF, RolimVM, NeuwaldEB, DriemeierD, ContesiniEA and Cirne-LimaE. (2016). Treatment of dilated cardiomyopathy in rabbits with mesenchymal stem cell transplantation and platelet-rich plasma. Vet J, 209:180–185.
55.
ChenQ, ZhangY, ZhuH, YuanX, LuoX, WuX, ChenS, ChenY, XuJ, et al. (2019). Bone marrow mesenchymal stem cells alleviate the daunorubicin-induced subacute myocardial injury in rats through inhibiting infiltration of T lymphocytes and antigen-presenting cells. Biomed Pharmacother, 121:109157.
56.
ChenM, FanZC, LiuXJ, DengJL, ZhangL, RaoL, YangQ and HuangDJ. (2006). Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin-induced heart failure. Cell Biol Int, 30:576–582.
57.
ChenY, LiuW, LiW and GaoC. (2010). Autologous bone marrow mesenchymal cell transplantation improves left ventricular function in a rabbit model of dilated cardiomyopathy. Exp Mol Pathol, 88:311–315.
58.
LuC, AraiM, MisaoY, ChenX, WangN, OnogiH, KobayashiH, UnoY, TakemuraG, et al. (2006). Autologous bone marrow cell transplantation improves left ventricular function in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms. Heart Vessels, 21:180–187.
59.
ZhangJ, LiGS, LiGC, ZhouQ, LiWQ and XuHX. (2005). Autologous mesenchymal stem cells transplantation in adriamycin-induced cardiomyopathy. Chin Med J (Engl), 118:73–76.
60.
ZhangY, YuZ, JiangD, LiangX, LiaoS, ZhangZ, YueW, LiX, ChiuSM, et al. (2016) iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF-alpha yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy. Stem Cell Rep, 7:749–763.
61.
ZhouC, YangC, XiaoS and FeiH. (2007) Feasibility of bone marrow stromal cells autologous transplantation for dilated cardiomyopathy. J Huazhong Univ Sci Technol Med Sci, 27:75–78.
62.
LipshultzSE and HermanEH. (2017). Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovasc Res, 114:205–209.
63.
Colafella KMM and DentonKM. (2018). Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol, 14:185–201.
64.
MeinersB, ShenoyC and ZordokyBN. (2018). Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. Biol Sex Differ 9:. 38.
65.
HaywardR and HydockDS. (2007). Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci, 46:20–32.
66.
KotwinskiP, SmithG, CooperJ, SandersJ, MaL, TeisA, KotwinskiD, MythenM, PennellDJ, JonesA and MontgomeryH. (2016). Body surface area and baseline blood pressure predict subclinical anthracycline cardiotoxicity in women treated for early breast cancer. PLoS One, 11:e0165262.
67.
CaiF, LuisMAF, LinX, WangM, CaiL, CenC and BiskupE. (2019). Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol, 11:15–23.
68.
TompkinsBA, BalkanW, WinklerJ, GyöngyösiM, GoliaschG, Fernández-AvilésF and HareJM. (2018). Preclinical studies of stem cell therapy for heart disease. Circ Res, 122:1006–1020.
69.
WenY, DingJ, ZhangB and GaoQ. (2018). Bone marrow-derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—a meta-analysis. Eur J Clin Invest. 48.
70.
ZhangJ, LinL and ZongW. (2018). Bone marrow mononuclear cells transfer for patients after ST-elevated myocardial infarction: a meta-analysis of randomized control trials. Yonsei Med J, 59: 611–623.
71.
van der SpoelTIG, Jansen of LorkeersSJ, AgostoniP, van BelleE, GyöngyösiM, SluijterJPG, CramerMJ, DoevendansPA and ChamuleauSAJ. (2011). Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res, 91:649–658.
72.
Martin-RendonE, BrunskillSJ, HydeCJ, StanworthSJ, MathurA and WattSM. (2008). Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J, 29:1807–1818.
73.
PerinEC, BorowKM, SilvaGV, DeMariaAN, MarroquinOC, HuangPP, TraverseJH, KrumH, SkerrettD, et al (2015). A Phase II Dose-Escalation Study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res, 117:576–584.
74.
LinW, HuangL, LiY, FangB, LiG, ChenL and XuL. (2019). Mesenchymal stem cells and cancer: clinical challenges and opportunities. BioMed Res Int, 2019:2820853.
75.
CuendeN, RicoL and HerreraC. (2012). Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation?. Stem Cells Transl Med, 1:403–408.
76.
LaluMM, McIntyreL, PuglieseC, FergussonD, WinstonBW, MarshallJC, GrantonJ and StewartDJ. (2012). Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One, 7:e47559.
77.
CismaruA, CismaruG. (2018). Optimal Delivery Strategy for Stem Cell Therapy in Patients with Ischemic Heart Disease. In: Stem Cells in Clinical Practice and Tissue Engineering. Sharma R, ed. IntechOpen Ltd, London, pp. 225–243.
78.
CaplanH, OlsonSD, KumarA, GeorgeM, PrabhakaraKS, WenzelP, BediS, Toledano-FurmanNE, TrioloF, et al. (2019). Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol, 10:1645.
79.
MullerP, LemckeH and DavidR. (2018). Stem cell therapy in heart diseases - cell types, mechanisms and improvement strategies. Cell Physiol Biochem, 48:2607–2655.
80.
DondersR, BogieJFJ, RavanidisS, GervoisP, VanheusdenM, MareeR, SchrynemackersM, SmeetsHJM, PinxterenJ, et al. (2018). Human Wharton's jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells Dev, 27:65–84.
81.
Abd AllahSH, HusseinS, HasanMM, DerazRHA, HusseinWF and SabikLME. (2017). Functional and structural assessment of the effect of human umbilical cord blood mesenchymal stem cells in doxorubicin-induced cardiotoxicity. J Cell Biochem, 118:3119–3129.
82.
MousaHSE, Abdel AalSM and AbbasNAT. (2018). Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: possible role of insulin-like growth factor-1. Biomed Pharmacother, 105:1192–1204.
83.
ZeissCJ, GattiDM, Toro-SalazarO, DavisC, LutzCM, SpinaleF, StearnsT, FurtadoMB and ChurchillGA. (2019). Doxorubicin-induced cardiotoxicity in collaborative cross (CC) mice recapitulates individual cardiotoxicity in humans. G3 (Bethesda), 9: 2637–2646.
84.
BartolucciJ, VerdugoFJ, GonzalezPL, LarreaRE, AbarzuaE, GosetC, RojoP, PalmaI, LamichR, et al. (2017). Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res, 121:1192–1204.
85.
HeldmanAW, DiFedeDL, FishmanJE, ZambranoJP, TrachtenbergBH, KarantalisV, MushtaqM, WilliamsAR, SuncionVY, et al. (2014). Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA, 311:62–73.
86.
BraunwaldE. (2018). Cell-based therapy in cardiac regeneration: an overview. Circ Res, 123:132–137.
87.
RoseRA, JiangH, WangX, HelkeS, TsoporisJN, GongN, KeatingSC, ParkerTG, BackxPH and KeatingA. (2008). Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells, 26:2884–2892.
88.
Musiał-WysockaA, KotM and MajkaM. (2019). The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant, 28:801–812.
89.
Scherrer-CrosbieM and ThibaultHB. (2008). Echocardiography in translational research: of mice and men. J Am Soc Echocardiogr, 21:1083–1092.
90.
RussoI, MicottiE, FumagalliF, MagnoliM, RistagnoG, LatiniR and StaszewskyL. (2019). A novel echocardiographic method closely agrees with cardiac magnetic resonance in the assessment of left ventricular function in infarcted mice. Sci Rep, 9:3580.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
